

PATENT ASSIGNMENT COVER SHEET

Electronic Version v1.1
Stylesheet Version v1.2

EPAS ID: PAT7600647

SUBMISSION TYPE:	NEW ASSIGNMENT
NATURE OF CONVEYANCE:	ASSIGNMENT
CONVEYING PARTY DATA	
Name	Execution Date
SUZHOU CUREMED BIOMEDICAL TECHNOLOGY CO. LTD.	09/23/2022
RECEIVING PARTY DATA	
Name:	PURECODON (HONG KONG) BIOPHARMA LTD.
Street Address:	16F FORTRESS TOWER, 250 KING'S RD.
Internal Address:	UNIT 1606, NORTH POINT
City:	HONG KONG
State/Country:	CHINA
Postal Code:	.
PROPERTY NUMBERS Total: 1	
Property Type	Number
Application Number:	17486204
CORRESPONDENCE DATA	
Fax Number:	(877)769-7945
<i>Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.</i>	
Phone:	+1 (650) 839-5097
Email:	apsi@fr.com
Correspondent Name:	JIA ZHU
Address Line 1:	FISH & RICHARDSON P.C.
Address Line 2:	P.O.BOX 1022
Address Line 4:	MINNEAPOLIS, MINNESOTA 55440-1022
ATTORNEY DOCKET NUMBER:	54524-0003002
NAME OF SUBMITTER:	LYNDZIE HAMM
SIGNATURE:	/Lyndzie Hamm/
DATE SIGNED:	10/20/2022
Total Attachments: 4	
source=Assignment#page1.tif	
source=Assignment#page2.tif	
source=Assignment#page3.tif	
source=Assignment#page4.tif	

ASSIGNMENT

Assignor: Suzhou Curemed Biomedical Technology Co. Ltd.
a corporation organized and existing under the laws of
China, and having a place of business at:
Room 201, Building 23, Tengfei Innovation Park, No. 388 Xiping Street, Suzhou
Industrial Park, Suzhou Area, Pilot Free Trade Zone,
Suzhou, Jiangsu, China, 215123

Assignee: PURECODON (HONG KONG) BIOPHARMA LIMITED
A corporation organized and existing under the laws of China, and having a place of
business at:
Unit 1606, 16F Fortress Tower, 250 King's Road, North Point, Hong Kong, China

Country	Application No.	Filing Date	Title
United States	17/436,204	9/27/2021	A RECOMBINANT NUCLEIC ACID MOLECULE OF TRANSCRIPTIONAL CIRCULAR RNA AND ITS APPLICATION IN PROTEIN EXPRESSION

1. Assignor represents that it is the owner of the patents and patent applications listed above, and of all foreign and domestic patents, patent applications, including continuation-in-part applications, reissues, re-examinations, certificates of invention, and the like that derive priority from, or claim the benefit of the filing date of, the patents and patent applications listed above (the "Patents and Patent Applications") and of all new and useful inventions and improvements that are disclosed in the Patents and Patent Applications (the "Inventions"). The Patents and Patent Applications and the Inventions are collectively referred to as the "Patent Assets."
2. Assignor hereby assigns to Assignee its entire worldwide right, title, and interest in and to the Patent Assets, including the right to file and prosecute, in Assignee's name wherever so permitted by law or in the name of Assignor wherever necessary, patent applications, including corresponding and continuing applications, reissues, re-examinations, certificates of invention, and the like based on any of the Patent Assets, and to claim priority to any of the Patents and Patent Applications pursuant to the International Convention for the Protection of Industrial Property, the Patent Cooperation Treaty, the European Patent Convention, and all other treaties of like purposes. Assignor acknowledges receipt of fair and adequate consideration for this Assignment.

3. Assignor shall, when requested by Assignee and at no cost to Assignor, (i) execute or cause to be executed all rightful oaths, assignments, and powers of attorney to Assignee or to agents and legal representatives of Assignee, and all other papers necessary and proper to carry out the intent and purpose of this Assignment, (ii) execute all papers necessary in connection with the Patents and Patent Applications, and any continuing, divisional, reissue, reexamination or other corresponding application thereof or post-grant proceeding relating thereto and to execute any separate assignment in connection with any such application as Assignee may deem necessary or expedient; and (iii) perform all affirmative acts that may be necessary to obtain a grant of a valid patent to Assignee on any of the Inventions.
4. Assignor hereby assigns to Assignee all of Assignor's right, title, and interest in and to any claims, whether known or unknown, suspected or unsuspected, of any nature, including choses in action, that Assignor has or may have against any party for infringement of the Patents and Patent Applications, and acknowledges receipt of fair and adequate consideration for this Assignment.
5. Assignor represents that Assignor has the full right to convey the interests assigned by this Assignment, and that Assignor has not executed and will not execute any agreement in conflict with this Assignment.
6. This Assignment is binding upon and inures to the benefit of the successors and assigns of the parties.

[ASSIGNMENT CONTINUES ON SIGNATURE PAGE]

The Assignor hereby executes this Assignment.

Assignor: Suzhou Curemed Biomedical Technology Co., Ltd.

Signature: Ping WANG

Date: Sep. 23, 2022

Name: Ping WANG

Title: Director

Witnessed by:

Signature: Feng ZHOU

Date: Sep. 23, 2022

Print Name: Feng ZHOU

Signature: Junjie GUAN


Date: Sep. 23, 2022

Print Name: Junjie GUAN

Assignment from Jiangsu PureCell Biomedical Technology Co. Ltd. to Suzhou Curedmed Biomedical Technology Co. Ltd.

The Assignee hereby acknowledges and accepts the foregoing assignment.

Assignee: PURECODON (HONG KONG) BIOPHARMA LIMITED

Signature: 

Date: Sep. 23, 2022

Name: LAU Ngai Cheung

Title: Director

Witnessed by:

Signature: Feng ZHOU

Date: Sep. 23, 2022

Print Name: Feng ZHOU

Signature: Junjie GUAN

Date: Sep. 23, 2022

Print Name: Junjie GUAN

100559053.doc